Webb12 feb. 2024 · Phillip Coffin, MD, MIA, Director, Substance Use Research Unit, San Francisco Department of Public Health: ClinicalTrials.gov Identifier: NCT03838510 Other Study ID Numbers: 5R01DA045690-02 ( U.S. NIH Grant/Contract ) First Posted: February 12, 2024 Key Record Dates: Last Update Posted: August 16, 2024 Last Verified: WebbPhillip Coffin, MD MIA San Francisco Department of Public Health University of California San Francisco [email protected] . Background Lay naloxone distribution is associated with reduced opioid overdose mortality (Walley et al., BMJ 2013)
Harm Reduction Practice and Innovation
Webb10 juni 2024 · Phillip O. Coffin, M.D., M.I.A., F.A.C.P., is the Director of Substance Use Research at the San Francisco Department of Public Health. He is board-certified in internal medicine, infectious diseases, and addiction medicine; specific foci of Dr. Coffin’s … WebbDr. Coffin spoke about the effectiveness of risk mitigation strategies for opioid treatment at a workshop organized by the National Institutes of Health. Phillip Coffin, MD Preliminary results of a 2014 survey showed that this practice is carried out in at least 16 states. dicker wolfsbalg wow classic
Philip Calvert, 5th Proprietary Governor of Maryland - Geni
Webb6 juli 2007 · Phillip Coffin, MD, MIA, Director of Substance Use Research, San Francisco Department of Public Health: ClinicalTrials.gov Identifier: NCT00497055 Other Study ID Numbers: 1R01DA022190-01 ( U.S. NIH Grant/Contract ) 1R01DA022190-01 ( U.S. NIH Grant/Contract ) 1R01DA023387-01 ( U.S. NIH Grant/Contract ) DPMC ( Other Identifier: … Webb4 sep. 2024 · Vivian Do, MPH student, Emily Behar, MS, PhD candidate, Caitlin Turner, MPH, Michelle Geier, PharmD, and Phillip Coffin, MD, MIA. Journal of Pharmacy Practice 2024 33: 3, 247-254 Download Citation. If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Webb21 mars 2024 · Event Date. March 21, 2024 2:00–3:00 pm EDT. Dr. Phillip Coffin will discuss and review the epidemiology of stimulant use, toxicities related to stimulants, and interventions. Learning Objectives: Explore epidemiology of stimulant use. Describe toxicities of simulant use. Identify interventions to address stimulant use. dicker wollpullover herren